Phase II, prospective, open-label study of a weekly schedule of irinotecan in patients with advanced colorectal cancer.

被引：0
|
作者：
Casinello, J
Dorta, J
Aguiar, J
Pérez-Carrión, J
Castellanos, J
Valladares, J
Sevilla, J
Belón, J
Fernández, J
Casal, J
机构：
[1] H Meixoeiro, Pontevedra, Spain
[2] H del Bierzo, Leon, Spain
[3] H Virgen de las Nieves, Granada, Spain
[4] H Virgen de la Victoria, Malaga, Spain
[5] H Juan Canalejo, La Coruna, Spain
[6] H Xeral Cies, Pontevedra, Spain
[7] H Princesa, Madrid, Spain
[8] H Gran Canarias, Madrid, Spain
[9] Na Sa Candelaria, Tenerife, Spain
[10] H Guadalajara, Tenerife, Spain
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
198P
引用
收藏
页码：46 / 46
页数：1
相关论文
共 50 条
  • [1] A Phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer.
    Cartwright, TH
    Lopez, T
    Vukelja, SJ
    Encarnacion, C
    Boehm, KA
    Asmar, L
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 284S - 284S
  • [2] Phase II study of capecitabine, irinotecan, and celecoxib in advanced colorectal cancer.
    El-Rayes, BF
    Shields, AF
    Vaishampayan, U
    Heilbrun, L
    Bekaii-Saab, T
    Zalupski, MM
    Philip, PA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 310S - 310S
  • [3] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Denise A. Yardley
    E. Claire Dees
    Stephen D. Myers
    Sherry Li
    Paul Healey
    Zhixiao Wang
    Marla J. Brickman
    Jolanda Paolini
    Kenneth A. Kern
    Dennis L. Citrin
    Breast Cancer Research and Treatment, 2012, 136 : 759 - 767
  • [4] Phase II open-label study of sunitinib in patients with advanced breast cancer
    Yardley, Denise A.
    Dees, E. Claire
    Myers, Stephen D.
    Li, Sherry
    Healey, Paul
    Wang, Zhixiao
    Brickman, Marla J.
    Paolini, Jolanda
    Kern, Kenneth A.
    Citrin, Dennis L.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 136 (03) : 759 - 767
  • [5] Combination of anlotinib and irinotecan in the second-line treatment of patients with advanced colorectal cancer: An open-label, multicenter phase I/II study.
    Zhang, Bo
    Wang, Xi
    Zhu, Lingjun
    Li, Qun
    Liu, Yun
    Qi, Ling
    Shu, Yongqian
    Huang, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients.
    Li, Wenhua
    Li, Jin
    Xu, Jianming
    Shen, Lin
    Liu, Tianshu
    Guo, Wei Jian
    Zhang, Wen
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Phase II study of irinotecan (CPT 11) in patients whit not pretreated advanced colorectal cancer.
    Salgado, M
    Menéndez, D
    Sabin, P
    Diz, P
    Constenia-Figueiras, M
    Casai, J
    Calvo, L
    Castellanos, J
    Balcells, M
    Firvida, JL
    Irigoyen, A
    Quintero, G
    Garcia-Palomo, A
    García-Arroyo, FR
    Huidobro, G
    Valladares, M
    Garcia-Mata, J
    Vázquez, S
    De las Peñas, R
    Lorenzo, I
    Xaries, J
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S74 - S74
  • [8] A multicenter, open-label phase II trial of secondline apatinib plus irinotecan in patients with advanced gastric cancer
    Peng, Jianjun
    Li, Yong
    Xiao, Jianjun
    Liu, Huaqiang
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] Efficacy and saftey of capecitabine, oxaliplatin, and irinotecan (xeloxiri) as salvage therapy for patients with treatment refractory metastatic colorectal cancer: A prospective, open-label, phase II study
    Yau, Thomas Cheung
    Tang, Vikki Y. F.
    Chiu, Joanne
    Wong, Hilda
    Leung, Roland Ching-Yu
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Cetuximab and irinotecan in weekly schedule in pretreated unselected advanced colorectal cancer patients PTS
    Cianci, Giovanni
    Durante, Valeria
    Giulia, Grassi A.
    Nuzzo, Carmen
    Nelli, Fabrizio
    Sperduti, Isabella
    Zeuli, Massimo
    Pollera, Camillo Franco
    Gamucci, Teresa
    D'Auria, Giuliana
    ANNALS OF ONCOLOGY, 2006, 17 : 124 - 124
12345